Sinocera 2025 Annual Report: Revenue of 4.583 Billion Yuan, Biomedical Materials Segment Revenue Up 2.11% Year-on-Year

Image source: Sinocera 2025 Annual Report

Net Profit Attributable to Shareholders of the Parent Company Increased by 0.91% / Goodwill from Upcera Dental Approximately 8.30 Billion CNY / Gross Profit Margin of Biomedical Materials Segment Declined Year-on-Year

DentalGoodNews | On April 21, 2026, Shandong Sinocera Functional Material Co., Ltd. (hereinafter referred to as "Sinocera") disclosed its 2025 Annual Report. The report shows that the company achieved annual operating revenue of 4.583 billion CNY, a year-on-year increase of 13.24%; the net profit attributable to shareholders of the listed company was 610 million CNY, a year-on-year increase of 0.91%. Among these, the net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was 605 million CNY, a year-on-year increase of 4.25%.

Regarding asset quality, the report disclosed that the goodwill amount in Sinocera's consolidated balance sheet reached 1.836 billion CNY. Among this, the goodwill generated from the acquisition of the business of Shenzhen Upcera Dental Technology Co., Ltd. was 830 million CNY, accounting for approximately 45% of the group's total goodwill. The auditing firm, Lixin Certified Public Accountants, listed the goodwill impairment of Upcera Dental, Yixing Prince Ceramics, and Sinocera Saichuang (totaling 1.667 billion CNY) as a key audit matter, focusing on significant accounting estimates and judgment risks.

Image source: Sinocera 2025 Annual Report

In terms of business performance, the biomedical materials segment achieved revenue of 930 million CNY in 2025, a year-on-year increase of 2.11%, with growth lower than the group's overall level. The segment's gross profit margin was 51.21%, a decrease of 5.46 percentage points compared to the same period last year. As of the end of the reporting period, Upcera Dental and its subsidiaries held 17 valid medical device product registrations and 5 product filings, with multiple all-ceramic material series achieving large-scale sales.

Geographical distribution shows that Sinocera's domestic revenue was 3.487 billion CNY, a year-on-year increase of 17.24%; overseas revenue was 1.095 billion CNY, a year-on-year increase of 2.17%. The company stated it will continue to deepen its presence in high-end markets in Europe and America and accelerate the global layout of biomedical materials. According to a previous report by DGN, Sinocera plans to acquire the Australian-listed dental consumables company SDI for approximately 816 million CNY.